tbuckley/cabot-search huggingface dataset:
Abstract 14591: Cost-Effectiveness of the American College of Cardiology/American Heart Association and US Preventative Services Task Force Cholesterol Management Guidelines: The Multi-Ethnic Study of Atherosclerosis
Authors: Jonathan C Hong, Rohan Khera, Javier Valero-Elizondo, Anshul Saxena, Michael J Blaha, Ron Blankstein, Michael D Miedema, Salim S Virani, Khurram Nasir
Journal: Circulation (2018)

Background: We evaluated the cost-effectiveness of the American College of Cardiology/American Heart Association (ACC/AHA) compared to the US Preventative Services Task Force (USPSTF) cholesterol m...
What proportion of athletes sustained an injury during a prospective study? Censored observations matter
Authors: Jonatan Jungmalm, Michael Lejbach Bertelsen, Rasmus Oestergaard Nielsen
Journal: British Journal of Sports Medicine (2019)

A common question in sports injury research is ‘what proportion of athletes sustained an injury over a certain time period?’. In cross-sectional studies, where data are collected at a single point in time, the prevalence proportion is simply the number of injured athletes divided by the total sample. In prospective cohort studies, caution is needed as the injury incidence proportion (proportion of newly injured athletes during the observation period) is likely to be underestimated by simply using the approach that is valid for cross-sectional studies. As a part of the BJSM methods matter series,1 we here compare the analytical approaches for cross-sectional studies and prospective cohort studies (ie, without censoring and with censoring, respectively) to help the reader accurately estimate incidence proportion in prospective studies.

To describe the proportion of sports injuries occurring over a given time period, one can calculate the CIP. The CIP can be calculated with or without censoring (in this paper, we discuss the concept of ‘right censoring’, but use the term ‘censoring’ only). For instance, the number of injured runners in a 1-year prospective cohort study was 252 of 931.2 Hence, the CIP calculated without censoring is 27% …
The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial
Authors: Yanhong Su, Jiajia Huang, Shusen Wang, Joseph M Unger, Jonathan Arias-Fuenzalida, Yanxia Shi, Jibin Li, Yongxiang Gao, Wei Shi, Xinyue Wang, Roujun Peng, Fei Xu, Xin An, Cong Xue, Wen Xia, Ruoxi Hong, Yongyi Zhong, Ying Lin, Heng Huang, Anqin Zhang, Lehong Zhang, Li Cai, Jinxin Zhang, Zhongyu Yuan
Journal: JNCI Journal of the National Cancer Institute (2019)

Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect. Ganglioside-monosialic acid (GM1) functions as a neuroprotective factor. We assessed the effects of GM1 on the prevention of TIPN in breast cancer patients.We conducted a randomized, double-blind, placebo-controlled trial including 206 patients with early-stage breast cancer planning to receive taxane-based adjuvant chemotherapy with a follow-up of more than 1 year. Subjects were randomly assigned to receive GM1 (80 mg, day -1 to day 2) or placebo. The primary endpoint was the Functional Assessment of Cancer Treatment Neurotoxicity subscale score after four cycles of chemotherapy. Secondary endpoints included neurotoxicity evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and the Eastern Cooperative Oncology Group neuropathy scale. All statistical tests were two-sided.In 183 evaluable patients, the GM1 group reported better mean Functional Assessment of Cancer Treatment Neurotoxicity subscale scores than patients in the placebo group after four cycles of chemotherapy (43.27, 95% confidence interval [CI] = 43.05 to 43.49 vs 34.34, 95% CI = 33.78 to 34.89; mean difference = 8.96, 95% CI = 8.38 to 9.54, P < .001). Grade 1 or higher peripheral neurotoxicity in Common Terminology Criteria for Adverse Events v4.0 scale was statistically significantly lower in the GM1 group (14.3% vs 100.0%, P < .001). Additionally, the GM1 group had a statistically significantly lower incidence of grade 1 or higher neurotoxicity assessed by Eastern Cooperative Oncology Group neuropathy scale sensory neuropathy (26.4% vs 97.8%, P < .001) and motor neuropathy subscales (20.9% vs 81.5%, P < .001).The treatment with GM1 resulted in a reduction in the severity and incidence of TIPN after four cycles of taxane-containing chemotherapy in patients with breast cancer.
Erratum: Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival (Journal of Experimental Botany (2014) 106:6 (dju085) DOI: 10.1093/jnci/dju085)
Authors: Y Cao, S Lindström, F Schumacher, V L Stevens, D Albanes, S I Berndt, H Boeing, H B Buenode-Mesquita, F Canzian, S Chamosa, S J Chanock, W R Diver, S M Gapstur, J M Gaziano, E L Giovannucci, C A Haiman, B Henderson, M Johansson, L Le Marchand, D Palli, B Rosner, A Siddiq, M Stampfer, D O Stram, R Tamimi, R C Travis, D Trichopoulos, W C Willett, M Yeager, P Kraft, A W Hsing, M Pollak, X Lin, J Ma
Journal: JNCI Journal of the National Cancer Institute (2014)
Lithotripsie EHL vs. LASER: étude in vitro
Authors: H Elbacha, F Prat
Journal: Endoscopy (2019)

La cholangiopancreatografie retrograde endoscopique consistue actuellement le traitement de référence des lithiases biliaires grâce à l'utilisation de paniers et/ou de ballonnets d'extractions. Cependant dans un petit nombre de cas (macrocalcul, lithiase intrahépatique) il peut etre necessaire de réaliser une lithotripsie intracorporelle par energie laser ou par énérgie éléctrohydraulique. Actuellement aucune étude pour évaluer l'efficacité comparative des deux techniques n'est disponible. l'objective de notre travail est de comparer l'efficacité des deux techniques sur modéle in vitro.
Abstract 10968: Risk Factors of Aortic Plaque Progression: Evaluation of Chronological Changes With Transesophageal Echocardiography
Authors: Chisato Izumi, Makoto Miyake, Masashi Amano, Yukiko Hayama, Naoki Onishi, Youdo Tamaki, Hirokazu Kondo, Toshihiro Tamura, Makoto Motooka, Kazuaki Kaitani, Yoshihisa Nakagawa
Journal: Circulation (2013)

Objectives: Aortic plaque may cause systemic embolism and patients with severe aortic plaque show poor prognosis. However, there are few data about chronological changes of aortic plaque. The purpo...
THE ROLE OF “ROSE” FOR ERCP-GUIDED BRUSHING ON INDETERMINATE BILIARY STRICTURES: EXPERIENCE OF A REFERRAL CENTER
Authors: L Archibugi, A Mariani, B Ciambriello, MC Petrone, G Rossi, SGG Testoni, M Traini, G Capurso, PG Arcidiacono
Journal: Endoscopy (2019)

Endoscopic Retrograde CholangioPancreatography (ERCP), although nowadays used only for therapeutic purposes, still has a prominent diagnostic role in patients with indeterminate biliary strictures and no evidence of mass lesion. The use of biliary stricture brushing is a safe, easy, cheap and fast way to acquire cytological specimen from the determination of the etiology, but the sensitivity can be as low as 50%. Rapid On-Site Evaluation (ROSE) of the sample has been used for years in referral centers for the determination of the adequacy of EUS-guided FNA cytological specimens, improving its sensitivity and specificity. Nevertheless, there are currently no studies evaluating its role for ERCP brushing. The aim of this study was to assess the diagnostic yield of ERCP brushing of indeterminate biliary strictures when supported by ROSE.
Association of Alternative Tobacco Product Initiation With Ownership of Tobacco Promotional Materials Among Adolescents and Young Adults
Authors: Hoda S. Abdel Magid, Patrick T. Bradshaw, Pamela M. Ling, Bonnie Halpern-Felsher
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Use of alternative tobacco products (ATPs) such as electronic cigarettes, chewing tobacco, pipes, cigars, cigarillos, little cigars, and hookah is rapidly increasing. Although marketing restrictions exist for cigarettes, marketing of ATPs is not yet fully regulated, and studies have not assessed the association between ownership of ATP promotional materials and subsequent ATP or cigarette initiation among adolescents and young adults. <h3>Objective</h3> To estimate the association between marketing receptivity measured at baseline and ATP and any tobacco initiation 1 year later, including cigarettes, among adolescents and young adults. <h3>Design, Setting, and Participants</h3> Longitudinal cohort study of adolescents and young adults aged 13 to 19 years recruited at high schools in California from July 2014 to October 2015, with follow-up 1 year later. Data were analyzed from January to March 2018. <h3>Exposures</h3> Ownership of ATP-specific promotional material and ownership of any tobacco promotional materials (eg, samples, coupons, branded caps, t-shirts, or posters) assessed in wave 1. <h3>Main Outcomes and Measures</h3> Outcomes were (1) ATP initiation and (2) either ATP or cigarette initiation in wave 2. <h3>Results</h3> Of 757 participants (mean [SD] age at wave 1, 16.1 [1.1] years; 481 [63.5%] female; 166 [21.9%] Asian or Pacific Islander, 202 [26.7%] white, and 276 [36.4%] Latino), 129 (17.0%) initiated ATP use and 141 (18.6%) initiated ATP or cigarette use 1 year later. In unadjusted models, wave 2 ATP initiation was found to be significantly associated with wave 1 ownership of ATP promotional materials (odds ratio, 2.23; 95% CI, 1.26-3.97). After adjustment for wave 1 demographic covariates, the association between ownership of ATP promotional material and ATP initiation 1 year later yielded similar results (odds ratio, 2.13; 95% CI, 1.16-3.91). Results of models assessing a combined outcome variable of either ATP or cigarette ever use were not statistically significant. <h3>Conclusions and Relevance</h3> Ownership of ATP promotional materials was associated with subsequent initiation of ATPs. The results of this study are consistent with the suggestion that current marketing restrictions for cigarettes, including restrictions of the distribution of samples, coupons, and other promotional material, should extend to ATPs.
Association of autoimmunity and cancer: An emphasis on proteolytic enzymes
Authors: Shams Tabrez, Nasimudeen R. Jabir, Mohammad Imran Khan, Mohd Shahnawaz Khan, Shazi Shakil, Ali Nasir Siddiqui, Syed Kashif Zaidi, Bakrudeen Ali Ahmed, Mohammad Amjad Kamal
Journal: Seminars in Cancer Biology (2019)
68Ga-DOTATATE PET Identifies Residual Myocardial Inflammation and Bone Marrow Activation After Myocardial Infarction
Authors: Jason M. Tarkin, Claudia Calcagno, Marc R. Dweck, Nicholas R. Evans, Mohammed M. Chowdhury, Deepa Gopalan, David E. Newby, Zahi A. Fayad, Martin R. Bennett, James H.F. Rudd
Journal: Journal of the American College of Cardiology (2019)

Myocardial infarction (MI) healing occurs in 2 phases: first an inflammatory phase, where clearance of necrotic debris occurs, followed by a reparative phase characterized by angiogenesis, granulation tissue formation, and attempts to repair the extracellular matrix. While efficient healing relies
Mechanisms associated with biogenesis of exosomes in cancer
Authors: Kathleen M. McAndrews, Raghu Kalluri
Journal: Molecular Cancer (2019)

Intercellular communication between cellular compartments within the tumor and at distant sites is critical for the development and progression of cancer. Exosomes have emerged as potential regulators of intracellular communication in cancer. Exosomes are nanovesicles released by cells that contain biomolecules and are exchanged between cells. Exchange of exosomes between cells has been implicated in a number of processes critical for tumor progression and consequently altering exosome release is an attractive therapeutic target. Here, we review current understanding as well as gaps in knowledge regarding regulators of exosome release in cancer.
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma
Authors: Andrés J. M. Ferreri, Teresa Calimeri, Gian Marco Conte, Dario Cattaneo, Federico Fallanca, Maurilio Ponzoni, Eloise Scarano, Flavio Curnis, Alessandro Nonis, Paolo Lopedote, Giovanni Citterio, Letterio S. Politi, Marco Foppoli, Stefania Girlanda, Marianna Sassone, Salvatore Perrone, Caterina Cecchetti, Fabio Ciceri, Claudio Bordignon, Angelo Corti, Nicoletta Anzalone
Journal: Blood (2019)
Does the gene matter? Genotype–phenotype and genotype–outcome associations in congenital melanocytic naevi
Authors: S. Polubothu, N. McGuire, L. Al‐Olabi, W. Baird, N. Bulstrode, J. Chalker, D. Josifova, D. Lomas, J. O'Hara, J. Ong, D. Rampling, P. Stadnik, A. Thomas, E. Wedgeworth, N.J. Sebire, V.A. Kinsler
Journal: British Journal of Dermatology (2019)

Genotype-phenotype studies can identify subgroups of patients with specific clinical features or differing outcomes, which can help shape management.To characterize the frequency of different causative genotypes in congenital melanocytic naevi (CMN), and to investigate genotype-phenotype and genotype-outcome associations.We conducted a large cohort study in which we undertook MC1R genotyping from blood, and high-sensitivity genotyping of NRAS and BRAF hotspots in 156 naevus biopsies from 134 patients with CMN [male 40%; multiple CMN 76%; projected adult size (PAS) > 20 cm, 59%].Mosaic NRAS mutations were detected in 68%, mutually exclusive with BRAF mutations in 7%, with double wild-type in 25%. Two separate naevi were sequenced in five of seven patients with BRAF mutations, confirming clonality. Five of seven patients with BRAF mutations had a dramatic multinodular phenotype, with characteristic histology distinct from classical proliferative nodules. NRAS mutation was the commonest in all sizes of CMN, but was particularly common in naevi with PAS > 60 cm, implying more tolerance to that mutation early in embryogenesis. Facial features were less common in double wild-type patients. Importantly, the incidence of congenital neurological disease, and apparently of melanoma, was not altered by genotype; no cases of melanoma were seen in BRAF-mutant multiple CMN, however, this genotype is rare.CMN of all sizes are most commonly caused by mutations in NRAS. BRAF is confirmed as a much rarer cause of multiple CMN, and appears to be commonly associated with a multinodular phenotype. Genotype in this cohort was not associated with differences in incidence of neurological disease in childhood. However, genotyping should be undertaken in suspected melanoma, for guidance of treatment. What's already known about this topic? Multiple congenital melanocytic naevi (CMN) have been shown to be caused by NRAS mosaic mutations in 70-80% of cases, by BRAF mosaicism in one case report and by inference in some previous cases. There has been debate about genotypic association with different sizes of CMN, and no data on genotype-outcome. What does this study add? NRAS mosaicism was found in 68%, BRAF in 7% and double wild-type in 25% of cases of CMN. NRAS was the commonest mutation in all sizes of CMN, but was nearly universal in projected adult size > 60 cm. BRAF is often associated with a distinct multinodular clinical/histological phenotype. Adverse outcomes did not differ between genotypes on current numbers.
AUTOMATIC POLYP DETECTION IN COLONOSCOPY – GENERAL COMPARISON OF SYSTEM AND VIDEO ANALYSIS STATISTICS
Authors: H Jacob, Y Kopelman, G Oren, P Siersema, A Cohen, R Eliakim, M Zaltshendler, D Zur
Journal: Endoscopy (2019)

The Automatic Polyp Detection System (APDS) was developed to enhance the ability of endoscopists to detect polyps during screening colonoscopy. The aim of this study was to compare performance of the trained system with a known database of 35 video sequences.
INFLUENCE OF ENDOSCOPIST EXPERIENCE, COMORBIDITIES AND PATIENTS AGE ON THE COMPLICATIONS AND DOSE OF SEDATION ON ENDOSCOPIC ULTRASOUND
Authors: M Razpotnik, S Bota, G Essler, J Weber-Eibel, M Peck-Radosavljevic
Journal: Endoscopy (2019)

To investigate the influence of endosonographer experience and patient related factors on the complications and dose of sedation by EUS.
ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION CYTOLOGY VS FINE NEEDLE BIOPSY FOR THE DIAGNOSIS OF PANCREATIC NEUROENDOCRINE TUMOURS
Authors: LH Eusebi, D Thorburn, C Toumpanakis, L Frazzoni, G Johnson, S Vessal, M Caplin, SP Pereira
Journal: Endoscopy (2019)

Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) as a method of obtaining preoperative diagnosis of pancreatic neuroendocrine tumours (PNETs) has been reported in several series. Fine needle biopsies (FNB) are increasingly employed to obtain core specimens during EUS. However, the differences in efficacy between these sampling methods in the diagnosis of PNETs still needs to be defined.
Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
Authors: Till Schoofs, Christopher O. Barnes, Nina Suh-Toma, Jovana Golijanin, Philipp Schommers, Henning Gruell, Anthony P. West, Franziska Bach, Yu Erica Lee, Lilian Nogueira, Ivelin S. Georgiev, Robert T. Bailer, Julie Czartoski, John R. Mascola, Michael S. Seaman, M. Juliana McElrath, Nicole A. Doria-Rose, Florian Klein, Michel C. Nussenzweig, Pamela J. Bjorkman
Journal: Immunity (2019)

Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are potential therapeutic agents. We identified SF12 and related bNAbs with up to 62% neutralization breadth from an HIV-infected donor. SF12 recognized a glycan-dominated epitope on Env's silent face and was potent against clade AE viruses, which are poorly covered by V3-glycan bNAbs. A 3.3Å cryo-EM structure of a SF12-Env trimer complex showed additional contacts to Env protein residues by SF12 compared with VRC-PG05, the only other known donor-derived silentface antibody, explaining SF12's increased neutralization breadth, potency, and resistance to Env mutation routes. Asymmetric binding of SF12 was associated with distinct N-glycan conformations across Env protomers, demonstrating intra-Env glycan heterogeneity. Administrating SF12 to HIV-1-infected humanized mice suppressed viremia and selected for viruses lacking the N448
MEASURING KRAS MUTATIONS IN PANCREATIC CYST FLUID BY DROPLET DIGITAL PCR AND NEXT-GENERATION SEQUENCING
Authors: NCM van Huijgevoort, F Dijk, JBG Halfwerk, SJ Lekkerkerker, RJ Reinten, P Fockens, MG Besselink, OR Busch, CJM van Noesel, MJ van de Vijver, J Verheij, JE van Hooft
Journal: Endoscopy (2019)

DNA-based testing of pancreatic cyst fluid, obtained with endoscopic ultrasound-fine needle aspiration (EUS-FNA), may be useful in the evaluation of pancreatic cystic neoplasms (PCN). Mutations in KRAS/GNAS are highly specific for mucinous pancreatic cystic neoplasm and can be detected by next generation sequencing (NGS; multiple genes simultaneously) or by droplet digital PCR (ddPCR; one gene at a time, but presumed higher sensitivity). The aim of this pilot study was to evaluate and compare NGS and ddPCR for measuring KRAS mutations in cyst fluid.
Unrecognized Obstructive Sleep Apnea and Postoperative Cardiovascular Complications
Authors: Dennis Auckley, Stavros Memtsoudis
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of BRCA1/2 mutations status on patient reported outcomes in HER2- advanced breast cancer: Results from a multi-country real-world study
Authors: A. Rider, R.G.W. Quek, K. Lewis, J. Kemp, A. Niyazov
Journal: Annals of Oncology (2019)

Background: Limited information is available on the effect of BRCA1/2 mutations on patient reported outcomes (PROs). This multi-country study assesses the impact of BRCA1/2 mutation status on patient demographics, cancer-related and breast cancer specific PROs in women with human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Methods: Oncologists extracted data from patient charts in adult women with HER2- ABC across the US and the United Kingdom, Spain, Germany, France and Italy (EU5) via the Adelphi Advanced Breast Cancer Disease Specific Program in 2017. A subset of patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) and the breast cancer module QLQ-BR23. Patients were categorized into 2 mutually exclusive cohorts; BRCA1/2 mutations (BRCAm) and BRCA wild type (BRCAwt). Differences in patient demographics were compared using t-tests and Pearson's Chi-squared tests. PROs were compared utilizing inverse probability weighted regression adjustment across multiple potential confounders. Results: Overall 199 patients participated; (BRCAm n = 37, BRCAwt n = 162). Patients with BRCAm were significantly younger (50.3 vs. 55.4 years old), [P = 0.018] and more likely have a family history of breast or ovarian cancer (43% vs. 22%), [P = 0.003] relative to BRCAwt. Significantly worse scores in role functioning (44.9 vs. 57.9), [P = 0.002] and dyspnea (47.7 vs. 37.0), [P = 0.012] were observed in patients with BRCAm relative to BRCAwt. No statistically significant differences in other EORTC PRO scales were observed. Conclusions: In this study of adult women with HER2- ABC, patients with BRCAm were significantly younger and more likely to have a family history of breast or ovarian cancer than BRCAwt. Patients with BRCAm reported significantly worse role functioning and dyspnea suggesting that BRCAm targeted treatment options leading to PROs improvements in these patients are needed. Legal entity responsible for the study: Pfizer. Funding: Pfizer. Disclosure: A. Niyazov: Employee, stockholder: Pfizer. R.G.W. Quek: Employee: Pfizer Inc.; Stock ownership: Pfizer Inc., Amgen Inc. All other authors have declared no conflicts of interest.
Screening for Familial Hypercholesterolemia
Authors: Stephen R. Daniels
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal